Search Result

Results for "

Spike

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (3) Angiotensin-converting Enzyme (ACE) (3) Autophagy (3) Casein Kinase (3) Cathepsin (1) CDK (1) Fatty Acid Synthase (FASN) (1) iGluR (3) Isotope-Labeled Compounds (1) Liposome (1) Potassium Channel (2) SARS-CoV (45) Virus Protease (1)
By Research Areas:	Cancer (5) Infection (43) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

169

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9801

*Anti-Spike-RBD mAb* 1 Publications Verification SARS-CoV-2 (2019-nCoV) Spike RBD Antibody	SARS-CoV	Infection
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .

HY-P9807

*Anti-SARS-CoV-2 Spike* mAb (CR3022)** SARS-CR3022; SARS-CoV-2 Antibody-CR3022	SARS-CoV	Infection Inflammation/Immunology
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .

HY-153235

*COVID-19 Spike* Protein mRNA-LNP**	SARS-CoV Liposome	Infection
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing *COVID-19 Spike* Protein*, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 Spike* Protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 Spike Protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

HY-P9802

*Anti-Spike-RBD Single Domain mAb* SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody	SARS-CoV	Infection
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .

HY-162295

SARS-CoV-2-IN-83

SARS-CoV Infection

SARS-CoV-2-IN-83 (compound C6E) has excellent activity against SARS CoV-2 spike protein .

SARS-CoV-2-IN-83	SARS-CoV	Infection
SARS-CoV-2-IN-83 (compound C6E) has excellent activity against SARS CoV-2 spike protein .

HY-153083

*COVID-19 Spike* Protein mRNA(N1-Me-Pseudo UTP)**	SARS-CoV	Infection
COVID-19 Spike Protein mRNA will express *COVID-19 spike* protein*, and suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 spike* protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 spike protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 spike protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

HY-149649

SARS-CoV-2-IN-64

SARS-CoV Infection

SARS-CoV-2-IN-64 (compound 9), a chenodeoxycholic acid derivative, is a potent inhibitor of spike glycoprotein of SARS-CoV-2 .

SARS-CoV-2-IN-64	SARS-CoV	Infection
SARS-CoV-2-IN-64 (compound 9), a chenodeoxycholic acid derivative, is a potent inhibitor of spike glycoprotein of SARS-CoV-2 .

HY-P99889

Romlusevimab BRII-198	SARS-CoV	Infection
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

HY-P99104

Plutavimab

COVI-AMG; STI-2020
SARS-CoV Infection

Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
HY-P990052

Simaravibart

MAD-0004J08
SARS-CoV Infection

Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .

Plutavimab COVI-AMG; STI-2020	SARS-CoV	Infection
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .

Simaravibart MAD-0004J08	SARS-CoV	Infection
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .

HY-157966

SARS-CoV-2 3CLpro-IN-23	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-23 (Compound Cd3) is a compound that can be isolated from Citrus depressa. SARS-CoV-2 3CLpro-IN-23 has good inhibitory activity to the SARS-CoV-2 spike protein, with K_D of 0.79 μM. SARS-CoV-2 3CLpro-IN-23 can bind to key amino acid residue, disrupting the formation of the spike protein and h-ACE2 complex .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-145644

Ogalvibart C-135-LS; BMS-986414	SARS-CoV	Infection
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .

HY-149940

SIMR3030	SARS-CoV	Infection
SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC₅₀ value of 0.0399 µg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice .

HY-144647

SP inhibitor 1	SARS-CoV Virus Protease	Infection
SP inhibitor 1 (compound 34) is a selective *SARS-CoV-2 spike* protein (SP) inhibitor with an IC₅₀ of 3.26 μM, >25 μM, >25 μM for SP, M ^pro and PL ^pro protein, respectively. SP inhibitor 1 is a vitro SARS-CoV-2 replication inhibitor at non-toxic concentrations (0.3250<5.98 μM). SP inhibitor 1 shows cellular antiviral** activity .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀ value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-14393

Emodin Maximum Cited Publications 17 Publications Verification Frangula emodin	SARS-CoV Casein Kinase Autophagy 11β-HSD	Cancer
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-161068

hACE2/SP-IN-1	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
hACE2/SP-IN-1 (compound 7a) is a dual inhibitor of hACE2 and coronavirus spike protein. hACE2/SP-IN-1 can bind to the spike protein and block cell entry, preventing SARS-CoV-2 from infecting human cells .

HY-163029

CTSL/B-IN-1	Cathepsin SARS-CoV	Infection
CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC₅₀s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .

HY-P3089

Dendrotoxin K	Potassium Channel	Others
Dendrotoxin K is a Kv1.1 channel blocker. Dendrotoxin K determines glutamate release in CA3 neurons in a time-dependent manner through the control of the presynaptic spike waveform .

HY-145641

Crexavibart BMS-986413; C-144-LS	SARS-CoV	Infection
Crexavibart (BMS-986413; C-144-LS) is an IgG1_λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .

HY-112829

Denifanstat 1 Publications Verification TVB-2640; FASN-IN-2; ASC-40	Fatty Acid Synthase (FASN)	Metabolic Disease Cancer
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC₅₀ of 0.052 μM and an EC₅₀ of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research .

HY-P3089A

Dendrotoxin K TFA	Potassium Channel	Others
Dendrotoxin K TFA is a Kv1.1 channel blocker. Dendrotoxin K TFA determines glutamate release in CA3 neurons in a time-dependent manner through the control of the presynaptic spike waveform .

HY-149256

PLpro/RBD-IN-1

SARS-CoV Infection

PLpro/RBD-IN-1 (compound 5) is a dual SARS-CoV-2 PLpro and spike protein RBD inhibitor with IC₅₀s of 7.197 μM and 8.673 μM, respectively .

PLpro/RBD-IN-1	SARS-CoV	Infection
PLpro/RBD-IN-1 (compound 5) is a dual SARS-CoV-2 PLpro and spike protein RBD inhibitor with IC₅₀s of 7.197 μM and 8.673 μM, respectively .

HY-P99346

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

HY-151267

SARS-CoV-2-IN-25	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-D1270

Direct Violet 1	SARS-CoV	Infection
Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the *SARS-CoV-2 spike* protein and ACE2 inhibitor with IC₅₀**s of 1.47-2.63 μM .

HY-151267A

SARS-CoV-2-IN-25 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) disodium is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 disodium inhibits enveloped viruses and liposomes .

HY-18663B

CP-465022 hydrochloride	iGluR	Neurological Disease
CP-465022 hydrochloride is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-138067

SSAA09E2	SARS-CoV	Inflammation/Immunology
SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) .

HY-18663A

CP-465022 maleate	iGluR	Neurological Disease
CP-465022 Maleate is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-18663

CP-465022	iGluR	Neurological Disease
CP-465022 is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-P9803

Anti-SARS-80R mAb SARS-80R; SARS Antibody-80R	SARS-CoV	Infection
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .

HY-P9805

Anti-MERS-3A1 mAb MERS-3A1; MERS Antibody-3A1	SARS-CoV	Infection
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .

HY-160554

C12-113	Others	Infection Inflammation/Immunology
C12-113 is a lipidoid delivery agent that can be used to transfect siRNA into cells. C12-113 can also be combined with other lipids to form lipid nanoparticles (LNPs) for the delivery of mRNA encoding the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice .

HY-P9806

Anti-MERS-D12 mAb MERS-D12; MERS Antibody-D12	SARS-CoV	Infection
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .

HY-P9804

Anti-MERS-2E6 mAb MERS-2E6; MERS Antibody-2E6	SARS-CoV	Infection
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.

HY-15275

BMS-265246	CDK Angiotensin-converting Enzyme (ACE)	Infection Cancer
BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC₅₀ values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research .

HY-151269

SARS-CoV-2-IN-26	SARS-CoV	Infection
SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC₅₀s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC₅₀ value of 4.4 μM .

HY-151276

SARS-CoV-2-IN-29	SARS-CoV	Infection
SARS-CoV-2-IN-29 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 exhibits antiviral activity with IC₅₀s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 induces liposomal membrane disruption with an EC₅₀ value of 3.0 μM .

HY-151278

SARS-CoV-2-IN-30	SARS-CoV	Infection
SARS-CoV-2-IN-30 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 exhibits antiviral activity with IC₅₀s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 induces liposomal membrane disruption with an EC₅₀ value of 6.9 μM .

HY-151271A

SARS-CoV-2-IN-27 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC₅₀s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC₅₀ value of 6.5 μM .

HY-151269A

SARS-CoV-2-IN-23 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-23 disodium is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 disodium exhibits antiviral activity with IC₅₀s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 disodium induces liposomal membrane disruption with an EC₅₀ value of 4.4 μM .

HY-151274

SARS-CoV-2-IN-28	SARS-CoV	Infection
SARS-CoV-2-IN-28 is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 exhibits antiviral activity with IC₅₀s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 induces liposomal membrane disruption with an EC₅₀ value of 4.4 μM .

HY-151271

SARS-CoV-2-IN-27	SARS-CoV	Infection
SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC₅₀s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC₅₀ value of 6.5 μM .

HY-151274A

SARS-CoV-2-IN-28 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-28 disodium is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 disodium exhibits antiviral activity with IC₅₀s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 disodium induces liposomal membrane disruption with an EC₅₀ value of 4.4 μM .

HY-151276A

SARS-CoV-2-IN-29 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-29 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 disodium exhibits antiviral activity with IC₅₀s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 disodium induces liposomal membrane disruption with an EC₅₀ value of 3.0 μM .

HY-151278A

SARS-CoV-2-IN-30 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-30 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 disodium exhibits antiviral activity with IC₅₀s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 disodium induces liposomal membrane disruption with an EC₅₀ value of 6.9 μM .

HY-145642

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

Cat. No.	Product Name	Target	Research Area

HY-P9801

*Anti-Spike-RBD mAb* 1 Publications Verification SARS-CoV-2 (2019-nCoV) Spike RBD Antibody	SARS-CoV	Infection
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .

HY-P9807

*Anti-SARS-CoV-2 Spike* mAb (CR3022)** SARS-CR3022; SARS-CoV-2 Antibody-CR3022	SARS-CoV	Infection Inflammation/Immunology
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .

HY-P99889

Romlusevimab BRII-198	SARS-CoV	Infection
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

HY-P9802

*Anti-Spike-RBD Single Domain mAb* SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody	SARS-CoV	Infection
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .

HY-P99104

Plutavimab

COVI-AMG; STI-2020
SARS-CoV Infection

Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
HY-P990052

Simaravibart

MAD-0004J08
SARS-CoV Infection

Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-145644

Ogalvibart C-135-LS; BMS-986414	SARS-CoV	Infection
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀ value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-145641

Crexavibart BMS-986413; C-144-LS	SARS-CoV	Infection
Crexavibart (BMS-986413; C-144-LS) is an IgG1_λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .

HY-P99346

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-P9803

Anti-SARS-80R mAb SARS-80R; SARS Antibody-80R	SARS-CoV	Infection
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .

HY-P9805

Anti-MERS-3A1 mAb MERS-3A1; MERS Antibody-3A1	SARS-CoV	Infection
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .

HY-P9806

Anti-MERS-D12 mAb MERS-D12; MERS Antibody-D12	SARS-CoV	Infection
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .

HY-P9804

Anti-MERS-2E6 mAb MERS-2E6; MERS Antibody-2E6	SARS-CoV	Infection
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.

HY-145642

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-145643

Nepuvibart ZRC3308-B10	SARS-CoV	Infection
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14393

Emodin 15+ Cited Publications Frangula emodin	Structural Classification Classification of Application Fields Polygonaceae Source classification Plants Endogenous metabolite Quinones Human Gut Microbiota Metabolites Microorganisms Rheum palmatum L. Anthraquinones Phenols Polyphenols Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-N1683

20(S),24(S)-Dihydroxydammar-25-en-3-one	Triterpenes Structural Classification Terpenoids Source classification Betula platyphylla Suk. Plants Betulaceae	Others
20(S),24(S)-Dihydroxydammar-25-en-3-one (compound 19) is a kind of triterpene. 20(S),24(S)-Dihydroxydammar-25-en-3-one can be isolated from the floral spikes of Betula platyphylla var. 20(S),24(S)-Dihydroxydammar-25-en-3-one has cytotoxicity against Human Cancer Cell Lines .

HY-14393R

Emodin (Standard) Frangula emodin (Standard)	Quinones Structural Classification Classification of Application Fields Rheum palmatum L. Polygonaceae Source classification Phenols Plants Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Standard) is the analytical standard of Emodin. This product is intended for research and analytical applications. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

Cat. No.	Product Name	Chemical Structure

HY-14393S

Emodin-d4

Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Species:	Virus (168) Human (1)
Tag:	His (145) SUMO (1) Tag Free (2) Avi (24) Myc (2) Fc (23) Flag (1)
Source:	HEK293 (137) Sf9 insect cells (3) Sf9 insect cells (27) P. pastoris (1) E. coli (1)


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Spike

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products